ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 12 (Supplement_1) S125 -133     DOI: 10.1677/erc.1.01024
Copyright © 2005 by the Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barrett-Lee, P J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrett-Lee, P J

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy

P J Barrett-Lee

Cardiff Breast Unit, Velindre NHS Trust, Cardiff CF14 2 TL, UK

(Requests for offprints should be addressed to Peter J Barrett-Lee; Email: Peter.Barrett-Lee{at}velindre-tr.wales.nhs.uk)

This paper was presented at the 1st Tenovus/AstraZeneca Workshop, Cardiff (2005). AstraZeneca has supported the publication of these proceedings.

Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed.




This article has been cited by other articles:


Home page
 JCOHome page
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al.
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
P.-S. Chen, M.-Y. Wang, S.-N. Wu, J.-L. Su, C.-C. Hong, S.-E. Chuang, M.-W. Chen, K.-T. Hua, Y.-L. Wu, S.-T. Cha, et al.
CTGF enhances the motility of breast cancer cells via an integrin-{alpha}vbeta3-ERK1/2-dependent S100A4-upregulated pathway
J. Cell Sci., June 15, 2007; 120(12): 2053 - 2065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger
Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response
Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar
Topoisomerase II{alpha} Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer
J. Clin. Oncol., June 1, 2006; 24(16): 2409 - 2411.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J M W Gee, A Howell, W J Gullick, C C Benz, R L Sutherland, R J Santen, L-A Martin, F Ciardiello, W R Miller, M Dowsett, et al.
Consensus Statement
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S1 - S7.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Endocrinology.